bemethyl (NP-135)
/ Algernon Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
October 20, 2020
"Only a few days until #ACG2020 Who's joining me? @musask @np4135 @Dr_YKReddy @GI_Jeremy @shailsingh"
(@mdmarathon)
January 31, 2019
Nash Pharmaceuticals to present pre-clinical data on non-alcoholic fatty liver disease at 2nd Global NASH Congress in London, UK
(GlobeNewswire)
- "Nash Pharmaceuticals Inc....is pleased to announce that it will be presenting its pre-clinical data on its non-alcoholic steatohepatitis ('NASH') research program at the upcoming Global NASH Congress, held in London, UK, February 25th & 26th, 2019. Results of a recently announced in vivo study, showed Nash Pharma’s lead compound NP-135 showed an 84.4% reduction in fibrosis."
Preclinical
January 31, 2019
Newly added product
(GlobeNewswire)
- Preclinical, Non-alcoholic Steatohepatitis, Chronic Kidney Disease
Pipeline update
1 to 3
Of
3
Go to page
1